Phase I II trial of ensartinib (X-396) in patients with ALK non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy Leora Horn1, Heather Wakelee2, Karen Reckamp3, Saiam - Genotyping - Document - PDFSEARCH.IO

First Page	Meta Content
	Phase I/II trial of ensartinib+ (X-396) in patients with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy Leora Horn1, Heather Wakelee2, Karen Reckamp3, Saiam Add to Reading List Document Date: 2017-01-03 23:04:13 Open Document File Size: 485,67 KB Share Result on Facebook

Phase I/II trial of ensartinib+ (X-396) in patients with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy Leora Horn1, Heather Wakelee2, Karen Reckamp3, SaiamAdd to Reading List